AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36328157
Drug: Edoxaban (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (once daily for 3 months)
Trial: 36328157
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SOC) anticoagulation (low molecular weight heparins or vitamin K antagonists)
Trial: 33615173
Drug: CIGB-325 (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIGB-325 (2.5 mg/kg/day during 5 consecutive days) plus standard-of-care
Trial: 34082177
Drug: 200 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/kg natural oregano essential oil (NOEO)
Trial: 34082177
Drug: 200 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/kg synthetic oregano essential oil (SOEO)
Trial: 34082177
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg colistin sulfate and 20 mg/kg virginiamycin (antibiotics)
Trial: 34082177
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (antibiotic-free)
Trial: 32081599
Drug: Memantine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (5 mg/d)
Trial: 32081599
Drug: Melatonin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (3 mg/d)
Trial: 32282773
Drug: Nonaggressive hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonaggressive hydration (Hartmann's solution at 1.5 mL kg h for the first 24 hours and 30 mL kg during the next 24 hours)
Trial: 32282773
Drug: Aggressive hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive hydration (bolus of Hartmann's solution 20 mL kg, followed by an infusion of 3 mL kg h for the first 24 hours and then 30 mL kg for the next 24 hours)
Trial: 36273180
Drug: Emotionally Focused
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emotionally Focused Therapy (EFT) for couples, 19-21 sessions
Trial: 33575950
Drug: IR‐ESO (esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR‐ESO (esomeprazole 20 mg and sodium bicarbonate 1100 mg)
Trial: 33575950
Drug: ESO (esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESO (esomeprazole delayed release tablet 20 mg)
Trial: 32006325
Drug: Polyethylene glycolated
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycolated exenatide injection (PB-119) at doses of 2-200 µg
Trial: 32006325
Drug: Polyethylene glycolated
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycolated exenatide injection (PB-119) at doses of 25-400 µg
Trial: 616996472
Drug: Pridopidine 45
RxNorm normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pridopidine 45 mg twice daily
Trial: 616996472
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg alone
Trial: 616996472
Drug: Pridopidine 90
RxNorm normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pridopidine 90 mg single dose
Trial: 32014029
Drug: Doll Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doll Therapy Intervention
Trial: 35489024
Drug: Control (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (chemotherapy without bevacizumab)
Trial: 33743851
Drug: Olaparib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (300 mg in two 150 mg tablets twice daily)
Trial: 35538754
Drug: Recombinant bovine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant bovine basic fibroblast growth factor gel
Trial: 35538754
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Erythromycin ointment)
Trial: 33238898
Drug: Continuous care
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous care (CC) by trained maternity care assistants (MCAs) during labor
Trial: 33238898
Drug: Continuous care
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous care (CC)
Trial: 33417699
Drug: Hierarchical Bayesian
RxNorm normalized name: Babesia microti preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hierarchical Bayesian model for drug response in cancer cell lines
Trial: 34492709
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise intervention (6-month, thrice weekly, moderate-vigorous intensity cycling)
Trial: 33050952
Drug: Specific Emotional‐Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific Emotional‐Cognitive Therapy (SECT)
Trial: 33050952
Drug: Emotion‐Focused Supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emotion‐Focused Supportive Therapy (EFST)
Trial: 32738573
Drug: Probiotic capsule
RxNorm normalized name: GNP Probiotic Capsule
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic capsule (PC)
Trial: 32738573
Drug: Control capsule
RxNorm normalized name: Azo Men Bladder Control Capsules(obs)
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control capsule (CC)
Trial: 38806190
Drug: adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adalimumab 40 mg every other week
Trial: 35574003
Drug: Premixed insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed insulin
Trial: 38914294
Drug: Monthly intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly intravitreal ranibizumab 0.5 mg
Trial: 33999371
Drug: High levels
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High levels of parathyroid hormone (PTH) in patients with positive histology for hepatic fibrosis, steatosis, and NASH/NAFLD
Trial: 36417812
Drug: Traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional therapy (Control group).
Trial: 36116147
Drug: Acellular carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular carbohydrate sources (e.g., flour‐based whole‐grain products)
Trial: 33196485
Drug: Immediate oral
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate oral refeeding (IORF) - low-fat-solid diet initiated immediately after hospital admission
Trial: 33196485
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral refeeding (CORF) - progressive oral diet restarted when clinical and laboratory parameters improved
Trial: 33196485
Drug: Immediate oral
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate oral refeeding (IORF)
Trial: 32560724
Drug: Saroglitazar (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saroglitazar (2 mg and 4 mg) and Pioglitazone
Trial: 35385141
Drug: Cold spray
RxNorm normalized name: Butane/Isobutane/Propane Topical application Spray [COLD SPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold spray placebo
Trial: 35901330
Drug: Chemotherapy (51.8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (51.8% of patients), with paclitaxel/carboplatin as the most common regimen.
Trial: 35287698
Drug: Oxycodone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone + naloxone (up to 20 mg per day)
Trial: 36300713
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum interleukin 2 receptor (sIL‐2R) levels
Trial: 34155332
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day of baclofen
Trial: 33247722
Drug: Aldosterone infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone infusion (0.2 and 5 ng min‐1 [L leg volume]‐1 for 10 minutes)
Trial: 33247722
Drug: Aldosterone infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone infusion with coinfusion of NAC (125 mg kg‐1 hour‐1 followed by 25 mg kg‐1 hour‐1)
Trial: 33247722
Drug: Aldosterone infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone infusion (both groups)
Trial: 36235571
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g erythritol
Trial: 36235571
Drug: 33.5 g
RxNorm normalized name: KETOPROFEN 33.5 g in 33.5 g TOPICAL POWDER, FOR SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33.5 g sucrose
Trial: 36235571
Drug: 0.0558 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0558 g sucralose
Trial: 32578066
Drug: Steroid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid group (hydrocortisone 500 mg before hepatic pedicle clamping, followed by 300 mg on POD 1, 200 mg on POD 2, and 100 mg on POD 3)
Trial: 32458450
Drug: Oropharyngeal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal administration of mother's milk (OPAMM) prior to gavage feeding (0.2 mL of mother's milk before each feeding)
Trial: 32458450
Drug: Oropharyngeal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oropharyngeal administration of mother's milk (OPAMM) prior to gavage feeding
Trial: 35728781
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics (500 mg azithromycin for 1 dose and 2 g cefazolin every 8 hours for up to 3 doses)
Trial: 35728781
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics (in class III obesity subgroup)
Trial: 32277384
Drug: Financial support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Financial support (up to 3 weekly financial transfers of $200 each)
Trial: 35536764
Drug: Febuxostat (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (40 mg or 80 mg once daily)
Trial: 35536764
Drug: Allopurinol (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (titrated in 100‐mg increments from 200‐400 mg or 300‐600 mg)
Trial: 36148748
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D3 supplementation (400 IU/day)
Trial: 33725800
Drug: topical pimecrolimus
RxNorm normalized name: pimecrolimus Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical pimecrolimus
Trial: 33725800
Drug: topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical tacrolimus
Trial: 34114408
Drug: Zhengyuan capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhengyuan capsule (8-week regimen)
Trial: 34114408
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule (8-week regimen)
Trial: 32539805
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative radiotherapy (SABR) followed by L19-IL2 therapy for oligo-metastatic patients; SABR to one (symptomatic) to a maximum of 5 lesions for poly-metastatic patients.
Trial: 32539805
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative radiotherapy (SABR) combined with immunotherapy (L19-IL2).
Trial: 33371058
Drug: Low-dose meropenem
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose meropenem (1g IV every 8 hours)
Trial: 33371058
Drug: High-dose meropenem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose meropenem (2g IV every 8 hours)
Trial: 33847098
Drug: Dietary-supplemented artichoke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary-supplemented artichoke (Cynara scolymus L.) at 3g/kg in the diet of laying hens.
Trial: 33847098
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving 130 g/day of compound feed for laying hens without artichoke supplementation.
Trial: 34076901
Drug: Ivermectin 12
RxNorm normalized name: Ivermectin 12 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 12 mg once daily for 3 days plus standard care
Trial: 34060937
Drug: MET409 (farnesoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET409 (farnesoid X receptor agonist)
Trial: 32958468
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise therapy and patient education (8-week program)
Trial: 36185085
Drug: Hewei Jiangni
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hewei Jiangni Decoction (HWJND) 81 g plus dummy omeprazole 20 mg daily for 8 weeks
Trial: 36185085
Drug: Dummy HWJND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy HWJND granules (81 g) plus omeprazole (20 mg)
Trial: 36242061
Drug: Kangyi Qiangshen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangyi Qiangshen Gong exercise prescription (KQG)
Trial: 35535708
Drug: Methenamine hippurate
RxNorm normalized name: Methenamine Hippurate
DrugBank: Methenamine (DB06799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methenamine hippurate (1g twice daily)
Trial: 32301701
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 250 mL of 0.9% normal saline containing 2 g cefuroxime sodium 30 minutes before surgery
Trial: 32301701
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: cefuroxime only after returning to ward, once daily for 3 consecutive days
Trial: 33359042
Drug: At-home treatment
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At-home treatment with 10% carbamide peroxide (2 h/day; 3 weeks)
Trial: 33359042
Drug: In-office treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-office treatment with 35% hydrogen peroxide (1/week; 3 weeks)
Trial: 33419086
Drug: Optimizing Background
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimizing Background Infusion Mode (OBIM)
Trial: 33419086
Drug: Traditional Background
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional Background Infusion Mode (TBIM)
Trial: 32833478
Drug: APPEAL intervention
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: APPEAL intervention (3 monthly, individually administered sessions)
Trial: 33681909
Drug: Unified protocol
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unified protocol combined with mindfulness treatment
Trial: 32673785
Drug: Rectal subregion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal subregion (V44-V74)
Trial: 33047859
Drug: BI 655064
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 655064 single doses (80-240 mg)
Trial: 33047859
Drug: BI 655064
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 655064 repeated doses (240 mg once weekly for 4 weeks)
Trial: 33047859
Drug: BI 655064
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 655064 (≥120 mg)
Trial: 35685052
Drug: Botulinum toxin‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin‐A injections and exercise
Trial: 35685052
Drug: Botulinum toxin‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin‐A injections, exercise, and dry needling
Trial: 34907724
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg oral daily)
Trial: 33021081
Drug: Ginsenoside H
RxNorm normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginsenoside H dripping pill (GH) at 7.8 mg
Trial: 33021081
Drug: Ginsenoside H
RxNorm normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginsenoside H dripping pill (GH) at 15.6 mg
Trial: 33021081
Drug: Ginsenoside H
RxNorm normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginsenoside H dripping pill (GH) at 31.2 mg
Trial: 33021081
Drug: Ginsenoside H
RxNorm normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginsenoside H dripping pill (GH) (multiple doses)
Trial: 34069951
Drug: Intravesical administration
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical administration of liposome-encapsulated BoNT-A
Trial: 34069951
Drug: Intravesical administration
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical administration of TC-3 hydrogel embedded BoNT-A
Trial: 34069951
Drug: Suprapubic energy
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprapubic energy shock wave (ESW) after BoNT-A intravesical administration
Trial: 32521325
Drug: Secukinumab treatment
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab treatment
Trial: 33863635
Drug: Colistin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin plus vitamin E (α‐Tocopherol) 400 units daily
Trial: 34891216
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg/day) + CoQ10 (2 × 200 mg/day)
Trial: 34891216
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg/day) + Placebo
Trial: 32040960
Drug: Triplex vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triplex vaccine
Trial: 32594785
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no medications)
Trial: 34164794
Drug: HTL0018318 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTL0018318 15 mg alone
Trial: 34164794
Drug: HTL0018318 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTL0018318 25 mg alone
Trial: 34164794
Drug: HTL0018318 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTL0018318 and donepezil combination
Trial: 33372602
Drug: Adjunctive air-polishing
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive air-polishing using nozzle+erythritol powder (test group, n=21)
Trial: 36308902
Drug: Diterpene Ginkgolides
RxNorm normalized name: terpene resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diterpene Ginkgolides Meglumine injection (DGMI)
Trial: 33648563
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) administration for 4 consecutive days
Trial: 34793406
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavior therapy (CBT)
Trial: 36034802
Drug: 0.2 mg/kg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg/week of PEG‐rhGH
Trial: 36034802
Drug: 0.14 mg/kg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.14 mg/kg/week of PEG‐rhGH
Trial: 35998550
Drug: Chemotherapy-Radiotherapy Interval
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy-Radiotherapy Interval (CRI) > 42 days
Trial: 35998550
Drug: Chemotherapy-Radiotherapy Interval
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy-Radiotherapy Interval (CRI) < 28 or 28-42 days
Trial: 33533941
Drug: Rheumatoid arthritis
RxNorm normalized name: Rheumatoid arthritis nuclear antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rheumatoid arthritis (RA) cohort not receiving RA therapy
Trial: 32429965
Drug: Integrated modular
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated modular teaching using different problem-based teaching methods (e.g., flipped classroom, team-based learning)
Trial: 33989234
Drug: Topical nonsteroid
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nonsteroid agents (tacrolimus and anti-vascular endothelial growth factor)
Trial: 37800194
Drug: Circadian Reinforcement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circadian Reinforcement Therapy (CRT)
Trial: 32702169
Drug: Tropifexor 60
RxNorm normalized name: Tropifexor
DrugBank: Tropifexor (DB16343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropifexor 60 µg
Trial: 35642398
Drug: rock salt
RxNorm normalized name: Nivea Men Rock Salts Body Wash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rock salt aerosol therapy
Trial: 35642398
Drug: conventional comprehensive
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional comprehensive treatment